Search

HAYWARD, Calif., Oct. 1, 2024 /PRNewswire/ -- Frontier Bio Corporation today announced a groundbreaking achievement in lab-grown lung tissue. By combining 3D bioprinting with the ability of stem cells to [...]

Program Enables Physicians to Request Molgramostim for Eligible Patients in Select Geographies Where the Product is Not Commercially Available and in Compliance with Local Regulatory Requirements LANGHORNE, Pa. -- Savara [...]

FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic [...]

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron [...]

-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo- -Treatment with Brensocatib Also [...]

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products [...]

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, announced today the [...]

DUBLIN, Jan. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI(revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic [...]

LIBERTY, Miss, Jan. 3, 2024 /PRNewswire/ -- Vitti Labs(TM), an AATB accredited tissue bank and life sciences company based in Liberty, MO, announced today that VL-PX10 and VL-P22, a first [...]

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX' or the 'Company'), a clinical-stage company advancing novel natural and engineered phage [...]

BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV1 [sup. 1 ] and C ystic F ibrosis Questionnaire - R evised (CFQ-R) respiratory domain in a predefined [...]

Researchers found 'statistically significant improvements' in lung function, respiratory symptoms, and quality of life measures for COPD patients CENTER VALLEY, Pa. , Nov. 20, 2023 /PRNewswire/ -- Olympus announced today [...]

Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN, Nov. 13, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4023995-1&h=68892083&u=http%3A%2F%2Fwww.viatris.com%2F&a=Viatris+Inc. (NASDAQ: [...]

Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN, Nov. 13, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4023889-1&h=1211249310&u=http%3A%2F%2Fwww.viatris.com%2F&a=Viatris+Inc. (NASDAQ: [...]

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class [...]

SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its pipeline into fibrosis with [...]

-QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications- [...]

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and [...]

LONDON, June 08, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today [...]

WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced [...]

Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. [...]

Proof-of-Concept study in SSc-ILD expected to begin in 2023. Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD. SAN DIEGO, March 01, [...]

BX004 therapy safe and well - tolerated across all patients and dose levels Preliminary signals of efficacy also observed , with notable reduc tions in bacterial burden Dosing in p [...]

Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on [...]

WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced [...]

2023 JUN 5 (VerticalNews) -- By a News Reporter-Staff News Editor at Internet Weekly News -- New research on Respiratory Tract Diseases and Conditions - Lung Diseases and Conditions is [...]

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide's lead [...]

Increasing Patients' Medication Adherence Can Improve Outcomes and Avoid Hospital Readmissions ROCKVILLE, Md., Dec. 6, 2022 /PRNewswire/ -- Patients with chronic heart disease and lung disease are more likely to [...]

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life REDWOOD CITY, Calif. & TOKYO -- [...]

-- Data show favorable safety, tolerability, and efficacy results -- -- All patients titrated to 250 ppm NO with no patients needing to reduce concentration -- -- All patients demonstrated [...]

Designation Validates Alvelestat's Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 (GLOBE NEWSWIRE) [...]

Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients Treatment-Refractory MAC Lung Disease Clinical Development Strategy to [...]

New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed [...]

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at the European Respiratory Society International Congress in [...]

CARY, NC , Aug 30, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin [...]

WARREN, N.J., Aug 15, 2022 (GLOBE NEWSWIRE via COMTEX) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, [...]

New Communications Brief in the journal Thorax reports survey findings that address tobacco company ownership in the making or selling of inhaler devices MIAMI -- Seventy percent (70%) of respondents [...]

SAN FRANCISCO, Aug. 8, 2022 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announces that the cyclosporine arm of the study has been terminated for [...]

Peroxitech, an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), recently reported the successful completion of a Series A financing round of $25 million led [...]

MENLO PARK, Jun 29, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:ANTX), EQNX::TICKER_END -- Phase 2/3 pivotal trial expected to support regulatory approval for treatment-refractory MAC lung disease; Plan to [...]